Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Zhejiang Cancer Hospital, National Cancer Center, National Cancer Center Hospital, Chongqing University, Chongqing Cancer Hospital, China Medical University, Samsung Medical Center, Sungkyunkwan University, Peking University Cancer Hospital, BeiGene (China), Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, Chinese PLA General Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379329015